Beam Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Beam Therapeutics Inc.
The gene-editing company has achieved proof-of-concept for its base-editing platform in three patients – but safety concerns have sent its share price into decline.
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.
Companies aiming to be fast followers in sickle cell disease gene therapy behind Vertex and bluebird have thinned out in 2023, and Beam may struggle to convince investors its base editing approach can compete.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Guide Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.